However, other studies with Gpr37 and Gpr37l1 null mutant models of seizure susceptibility, ischemic stroke, and central cardiovascular control have not confirmed the co-expression of prosaposin and the two putative receptors, or the prosaptide-mediated activation of their intracellular signaling [31,40,44]. The gene discussed is GPR37; the disease is ischemic stroke.